ClinicalTrials.gg
RecruitingNCT07051486Updated Nov 17, 2025

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

A Phase 2 interventional study of SHR-A1811 Injection in Recurrent or Metastatic Cervical Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Primary conditionUterine Cervical NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Cervical Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Uterine Cervical Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
196th of 360
60 · median 90
Started
2025
with 43 others
Phase 2
137 of 455
71 open now
Primary completion
2026-02
later than 104 of 239 live
Registered
406th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 196th largest by planned enrollment of the 360 interventional ones that give a count, is one of 44 that started in 2025, is one of 137 in phase 2, reaches primary completion later than 104 of the 239 other live ones, and was the 406th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

199 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.

03

Conditions studied

  • Recurrent or Metastatic Cervical Cancer

Browse trials for

04

In context

Uterine Cervical Neoplasms Reclassified

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Compared within Uterine Cervical Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily join this study, sign the , have good compliance, and can cooperate with follow-up.
  2. Female, aged 18-75 years old (including 18 and 75 years old, calculated on the day of signing the informed consent).
  3. Cervical cancer confirmed by tissue or cytological pathology.
  4. Expected survival ≥ 12 weeks.
  5. Normal function of important organs.
  6. Female subjects of fertility must have a negative serum HCG test within 7 days before the first dose of Medicinal Product (IMP), and must not be breastfeeding, and must agree to comply with requirements from the signing of the informed consent until the last dose of the trial drug for 7 months.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known untreated or active central nervous system (CNS) tumor .
  2. Subjects with other malignant tumors in the past or at the same time.
  3. Subjects with clinically symptomatic, poorly controlled, or moderate or greater pleural effusion, pericardial effusion or peritoneal effusion.
  4. Subjects with a history of interstitial pneumonia/interstitial lung disease or non-infectious pneumonia requiring treatment.
  5. Subjects with , connective tissue or inflammatory diseases involving the lungs.
  6. Subjects with known lung damage caused by concurrent lung diseases.
  7. Subjects with active pulmonary tuberculosis.
  8. Subjects with poorly controlled or severe cardiovascular diseases.
  9. Subjects with arterial/venous thrombotic events within 1 month before enrollment.
  10. Subjects who had a serious infection within 1 month before enrollment.
  11. History of immunodeficiency, including positive test.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SHR-A1811 Group

    Drug: SHR-A1811 Injection

Interventions

07

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) assessed by Independent Review Committee (IRC)

    Time frame: Up to 2 years.

Secondary outcomes

  1. Overall survival (OS) assessed by Independent Review Committee (IRC)

    Time frame: Up to 2 years.

  2. Overall survival (OS) assessed by investigators

    Time frame: Up to 2 years.

  3. Progression free survival (PFS) assessed by Independent Review Committee (IRC)

    Time frame: Up to 2 years.

  4. Progression free survival (PFS) assessed by investigators

    Time frame: Up to 2 years.

  5. Duration of response (DoR) assessed by Independent Review Committee (IRC)

    Time frame: Up to 2 years.

  6. Duration of response (DoR) assessed by investigators

    Time frame: Up to 2 years.

  7. Disease control rate (DCR) assessed by Independent Review Committee (IRC)

    Time frame: Up to 2 years.

  8. Disease control rate (DCR) assessed by investigators

    Time frame: Up to 2 years.

  9. Objective response rate (ORR) assessed by investigators

    Time frame: Up to 2 years.

  10. Adverse events (AEs)

    Time frame: Up to 2 years.

  11. Serious adverse events (SAEs)

    Time frame: Up to 2 years.

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's planned 4 months is below that.

Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Oct 11, 2025
Primary completionEst.
Feb 2026
CompletionEst.
Aug 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07051486
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Oct 11, 2025
Primary completion
Feb 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Nov 17, 2025

Study contacts

Na An
Contact
na.an@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion